<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812654</url>
  </required_header>
  <id_info>
    <org_study_id>1947/14</org_study_id>
    <nct_id>NCT02812654</nct_id>
  </id_info>
  <brief_title>Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment</brief_title>
  <official_title>The Use of Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Treatment of High-grade Extremity Soft Tissue and Non-metastatic Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AC Camargo Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AC Camargo Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective phase II study. Patients will be submitted to neoadjuvant chemotherapy (cT) and
      hypo fractionated radiotherapy (hRT) following by surgery. The remain viable cells will be
      analyzed and the patients whithin less than 30% will receive more 3 cycles of cT. All
      patients have deep high grade soft tissue sarcoma of extremity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective phase II non controlled study. Staging: All patients will be submitted to a local
      Magnetic Resonance (MR), Chest Tomography (CT) and Positron emission tomography-computed
      tomography (PET CT) previous to treatment. After the first cT cycle a new PET CT will be
      provided and one more at the end of the neoadjuvant treatment. Chemotherapy: cT neoadjuvant:
      Doxorubicin 75mg/m2 (cycles 1,2 and 3), and ifosfamide 9 g/m2 (cycles 1 and 3). Radiotherapy:
      RT 25 Gy / 5 x 500 cGy/day, beginning at Cycle 2/Day1. The surgery will be performed after
      4-6 weeks from cycle 3. The remain of viable cells in surgical specimen will be analyzed and
      whether the the percentage value is less than 30% the patient will receive more 3 cycles of
      cT. A boost of RT is indicated if margins are considered R1 (microscopic positive margin).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate disease free survival after neoadjuvant treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate local and distant disease free survival after the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate wound complication rates</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate if this treatment is comparable with the Institution previous results using only cT as neoadjuvant treatment (20% of wound complications).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rates</measure>
    <time_frame>30 days</time_frame>
    <description>Evaluate if it can be maintained the amputation rate (less than 5%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cT morbidity</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the morbidity rates related to cT scheme</description>
  </secondary_outcome>
  <other_outcome>
    <measure>PET CT response</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate if the SUV (Standard uptake value) varies after first and third cycle and if it is related to survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Sarcoma, Soft Tissue</condition>
  <arm_group>
    <arm_group_label>Doxorubicin, Ifosfamide, radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorubicin 75mg/m2 (cycle 1,2 and 3), ifosfamide 9 g/m2 (cycle 1 and 3) and radiotherapy: 25 Gy / 5 x 500 cGy/day, beginning at Cycle2/Day1. The surgery will performed after 4-6 weeks from cycle 3. The remain viable cells in surgical specimen will be analyzed and if it accounts less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 75mg/m2 (cycle 1,2 and 3)</description>
    <arm_group_label>Doxorubicin, Ifosfamide, radiotherapy</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Ifosfamide 9 g/m2 (cycle 1 and 3)</description>
    <arm_group_label>Doxorubicin, Ifosfamide, radiotherapy</arm_group_label>
    <other_name>Mitoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>radiotherapy: 25 Gy / 5 x 500 cGy/day</description>
    <arm_group_label>Doxorubicin, Ifosfamide, radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18-75 years old, with non metastatic deeply high grade soft tissue
             sarcoma of extremities. KPS &gt; 70% (Karnofsky Performance Status Score)

        Exclusion Criteria:

          -  Patients with rhabdomyosarcoma, neuroendocrine tumor (Pnet) and chondrosarcomas, or
             who have had received radiotherapy (RT) or chemotherapy (cT) previous, or recurrent
             tumors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ademar Lopes, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.C.Camargo Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ademar Lopes, Phd</last_name>
    <phone>55-11-2189-5000</phone>
    <phone_ext>2304</phone_ext>
    <email>ademar-lopes@uol.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ranyell S Batista, Phd</last_name>
    <phone>55-11-2189-5000</phone>
    <phone_ext>2304</phone_ext>
    <email>ranyell.spencer@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.C.Camargo Cancer Center</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>Sao Paulo</state>
        <zip>CEP 01509 - 010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruna C Kupper, Nurse</last_name>
      <phone>55-11-21895000</phone>
      <phone_ext>2946</phone_ext>
      <email>bruna.sousa@accamargo.org.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Aguiar Junior S, Ferreira Fde O, Rossi BM, Santos EM, Salvajoli JV, Lopes A. Neoadjuvant chemoradiation therapy for soft tissue sarcomas of the extremities. Clinics (Sao Paulo). 2009;64(11):1059-64. doi: 10.1590/S1807-59322009001100005.</citation>
    <PMID>19936179</PMID>
  </reference>
  <reference>
    <citation>Aguiar S Jr, da Cunha IW, Lopes A. Genomic expression, chemotherapy response, and molecular targets in soft tissue sarcomas of the extremities: promising strategies for treatment selection. J Surg Oncol. 2010 Jan 1;101(1):92-6. doi: 10.1002/jso.21422. Review.</citation>
    <PMID>19834919</PMID>
  </reference>
  <reference>
    <citation>Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15;15(8):2856-63. doi: 10.1158/1078-0432.CCR-08-2537. Epub 2009 Apr 7.</citation>
    <PMID>19351756</PMID>
  </reference>
  <reference>
    <citation>Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004 Nov 15;22(22):4567-74.</citation>
    <PMID>15542808</PMID>
  </reference>
  <reference>
    <citation>Eilber FC, Rosen G, Nelson SD, Selch M, Dorey F, Eckardt J, Eilber FR. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003 Feb;237(2):218-26.</citation>
    <PMID>12560780</PMID>
  </reference>
  <reference>
    <citation>Freedman GM. Hypofractionated radiation therapy in the treatment of early-stage breast cancer. Curr Oncol Rep. 2012 Feb;14(1):12-9. doi: 10.1007/s11912-011-0207-7. Review.</citation>
    <PMID>22071682</PMID>
  </reference>
  <reference>
    <citation>Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, Singer S. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004 Nov;15(11):1667-72.</citation>
    <PMID>15520069</PMID>
  </reference>
  <reference>
    <citation>Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG, Picci P. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012 Mar 10;30(8):850-6. doi: 10.1200/JCO.2011.37.7218. Epub 2012 Feb 6.</citation>
    <PMID>22312103</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>neoadjuvant radiotherapy</keyword>
  <keyword>hypofractionated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

